3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
6
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
16
Myelodysplastic Syndromes
12
Multiple Myeloma
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Hematologic Neoplasms
6
Neuroblastoma
5
Hodgkin Disease
5
Retinoblastoma
4
Lymphoma, Non-Hodgkin
4
Graft vs Host Disease
4
Anemia, Refractory, with Excess of Blasts
4
Myeloproliferative Disorders
3
Leukemia, Myelomonocytic, Chronic
3
Recurrence
2
Primary Myelofibrosis
2
Myelodysplastic-Myeloproliferative Diseases
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Leukemia
2
Ganglioneuroblastoma
2
Anemia, Aplastic
2
beta-Thalassemia
1
Venentoclax
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Interventions
Capecitabine
29
Oxaliplatin
28
Fluorouracil
16
Radiotherapy
15
Drug Therapy
11
Leucovorin
10
Bevacizumab
10
Surgical Procedures, Operative
9
Chemoradiotherapy
8
Radiation
7
sintilimab
6
Consolidation Chemotherapy
6
tislelizumab
5
spartalizumab
5
XELOX
5
Specimen Handling
5
Irinotecan
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
Neoadjuvant Therapy
4
Endoscopy
4
Cetuximab
4
Biopsy
4
toripalimab
3
pembrolizumab
3
irinotecan sucrosofate
3
X-Rays
3
Radiotherapy, Intensity-Modulated
3
Proctectomy
3
Mastectomy, Segmental
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Rectal Neoplasms
×
Melphalan
×
Clear all
NCT06607458
2026-03-13
DEL-LIVER
Delcath Systems Inc.
Phase 2
Recruiting
90 enrolled